UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
FRAZIER KENNETH C
( Last ) ( First ) ( Middle )
MERCK & CO., INC., 2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)
11/9/2020

4. If Amendment, Date Original Filed (MM/DD/YYYY)

5. Relationship of Reporting Person(s) to Issuer
Chairman, President & CEO

6. Individual or Joint/Group Filing
Form filed by One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Trans. Execution Date, if any</th>
<th>Securities Acquired or Disposed of (D)</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>11/9/2020</td>
<td>S</td>
<td>135134</td>
<td>D</td>
<td>581.0756</td>
<td>1</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/9/2020</td>
<td>S</td>
<td>144866</td>
<td>D</td>
<td>581.7372</td>
<td>1</td>
</tr>
<tr>
<td>Common Stock - 401(k) Plan</td>
<td>11/9/2020</td>
<td>S</td>
<td>4208.2792</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivate Security</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Securities Acquired or Disposed of (D)</th>
<th>Exercisable or Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.41 to $81.39, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.40 to $82.33, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

3. Holdings include shares acquired in dividend reinvestment transactions.

4. Includes shares acquired and dividends earned through October 7, 2020, in the Merck U.S. Savings Plan, a 401(k) plan.

Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRAZIER KENNETH C MERCK &amp; CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033</td>
<td>Chairman, President &amp; CEO</td>
</tr>
</tbody>
</table>

Signatures

/s/ Jon Filderman as Attorney-in-Fact for Kenneth C. Frazier

Date 11/12/2020
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.